BioLine RX Ltd
Change company Symbol lookup
Select an option...
BLRX BioLine RX Ltd
BLPH Bellerophon Therapeutics Inc
BLNK Blink Charging Co
CTXS Citrix Systems Inc
AFHIF Atlas Financial Holdings Inc
RIOCF RioCan Real Estate Investment Trust
OMP Oasis Midstream Partners LP
GMED Globus Medical Inc
TSN Tyson Foods Inc
VOO Vanguard S&P 500 ETF
Go

Health Care : Biotechnology | Small Cap Value
Based in Israel
Company profile

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Premarket

Last Trade
Delayed
$2.77
-0.18 (-6.10%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$2.95
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
82

10-day average volume:
1,283,936
82

Biden's 'rescue America' plan is big. How its trillions could help both Wall Street and Main Street

9:33 am ET January 16, 2021 (MarketWatch)
Print

By Joy Wiltermuth

As Americans hunker down and wait to get vaccinated, the toll of the coronavirus pandemic keeps rising.

Its costs, both in lives and livelihood, prompted President-elect Joe Biden on Thursday to propose another $1.9 trillion "first step (https://www.marketwatch.com/story/biden-called-his-1-9-trillion-relief-plan-the-first-step-heres-his-idea-for-part-two-11610731909?mod=home-page)" spending package to help combat the carnage of the pandemic, even before he takes office next week.

But as Washington gears up to debate another big relief initiative, hand-wringing on Wall Street has already begun as investors worry the bull-market for stocks could be threatened (https://www.marketwatch.com/story/majority-of-investors-say-higher-rates-loom-as-biggest-threat-to-stocks-and-risky-assets-from-rallying-further-says-bofa-survey-11610727274?mod=markets_seemore)by an economy that might overheat and cause borrowing costs to rise, while also potentially saddling the U.S. with unsustainable debts.

"It's a tug of war," said Bryce Doty, senior portfolio manager at Sit Investment Associates, in Minneapolis. "The current situation is horrible, but six months ahead, we hope a lot more people will be vaccinated."

Equity markets have largely looked beyond this winter's dire chapter of soaring COVID-19 (https://www.marketwatch.com/story/global-deaths-from-covid-19-near-2-million-as-us-suffers-most-weekly-fatalities-since-start-of-the-pandemic-2021-01-15?mod=coronavirus-update)infection rates and deaths, and the resumption of lockdowns across swaths of the U.S., Europe and China. The focus instead has been on the vaccine rollout and expectations for the incoming Biden administration to secure more funding from Congress to bridge the economy through the coronavirus crisis.

Biden pointed to a "crisis of deep human suffering" on Thursday that is "in plain sight," while urging Congress, soon to be controlled by Democrats, to authorize $1 trillion to get another $1,400 in direct payments to households, as well as $440 billion to reeling small businesses and $20 billion to speed up what he called a "dismal failure" of the national vaccination program.

Check out: Biden economic plan to test Congress' COVID relief fatigue (https://www.marketwatch.com/story/biden-economic-plan-to-test-congress-covid-relief-fatigue-11610743219?mod=economy-politics)

If passed, total spending from Congress in the past year on coronavirus aid would reach $4.8 trillion, plus the Federal Reserve's huge monetary stimulus and bond- buying program that's expanded its balance sheet (https://www.federalreserve.gov/monetarypolicy/bst_recenttrends.htm) to about $7.3 trillion from $4.2 trillion as of last February, writes MarketWatch columnist Michael Brush (https://www.marketwatch.com/story/here-are-the-biggest-stock-market-winners-and-losers-in-bidens-massive-stimulus-plan-11610732956?mod=article_inline).

"On the one hand, you have investors worrying about the Fed pulling back from stimulus, while the Biden administration wants to throw a ton more stimulus at the pandemic," Doty told MarketWatch. "But the more Biden's stimulus packs a punch, the sooner the Fed will start pulling back."

Federal Reserve Chair Jerome Powell said talk of bond-buying tapering by the Fed was premature, during a virtual talk Thursday (https://www.marketwatch.com/story/feds-powell-downplays-risk-of-persistently-higher-inflation-11610649051?mod=mw_latestnews)hosted by Princeton University's Bendheim Center for Finance.

Powell also said the Fed wants to avoid "people losing the lives they've made" because of the pandemic.

The Biden administration plans to act fast to provide relief where it's needed most. Top priorities include dramatically ramping up vaccinations, helping hard-hit restaurants feed the hungry, and getting K-8 grade schools to safely reopen.

"We will have to move heaven and earth," Biden said of his goal to get 100 million vaccinated against COVID-19 in his first 100 day (https://www.marketwatch.com/story/biden-promises-100-federal-vaccination-centers-by-end-of-his-first-month-in-office-11610746400?mod=mw_latestnews)s in office, as well as his broader rescue plan that some view as a "lifeline" that can't come a moment too soon (https://www.marketwatch.com/story/lifeline-to-workers-why-bidens-call-for-a-19-billion-covid-19-rescue-package-has-not-come-a-moment-too-soon-2021-01-14?mod=mw_latestnews).

Laura Veldkamp, a professor of finance at Columbia University's business school, compared money spent to bolster the U.S. economy to investment decisions made in the business world.

"If a U.S. company went on a huge spending spree on low-value projects, it wouldn't remain solvent for long," she told MarketWatch. But if a company opts to instead invest in valuable projects, particularly at today's low rates, it likely will thrive, she said.

"A lot of spending on COVID, that's super high-value," Veldkamp said. But she also sees the potential risk the Biden plan carries for markets. "We are in a position where there's a lot of money in circulation," she said, warning that could spark inflation and future Fed interest rate hikes, which would lift rates above today's near-zero range.

"But I don't think we should let marginalized communities suffer," she said, pointing to investor fears of rate hikes that become a possibility "at some point" down the road, particularly since two, prior rounds of fiscal stimulus already have been coursing through the economy, "and we still have really, really low inflation."

Minneapolis Fed President Neel Kashkari on Friday said there's little risk of inflating shooting way above 2% (https://www.marketwatch.com/story/feds-kashkari-says-hes-not-worried-about-inflation-shooting-way-above-2-rate-11610731005?mod=federal-reserve), but that even if it does, the Fed has tools to deal with it.

Investors have been concerned about being blindsided by any changes in the Fed's current easy-money policies, but more so this month as 10-year Treasury yields inched back above 1% (https://fred.stlouisfed.org/series/DGS10). That compares with a yield of about 1.5% to 3.5% for much of the past decade.

U.S. stocks closed lower for the week on Friday, as investors balanced worries about the potential for Biden's rescue plan to be partially paid for through higher taxes, including for corporations that could weigh on earnings, against hopes that giving households and businesses additional aid would spell a stronger economic rebound.

The Dow Jones Industrial Average lost 0.9% for the week, the S&P 500 index 1.5% and technology-heavy Nasdaq Composite Index 1.5%, according to FactSet data.

Even with a robust vaccine rollout planned for the months ahead, that doesn't necessarily mean highflying technology stocks that charged higher in during the pandemic are doomed to see prices fall, particularly as more people have gotten comfortable shopping online, working from home and investing in greener companies.

"The areas that Biden will emphasize have had good moves already," said Rhys Williams, chief investment officer at Spouting Rock Asset Management, in Bryn Mawr, Pa., speaking of renewable energy plays, but also stocks that could see a boost from Biden's digital infrastructure plans. "I think they still belong in a portfolio."

Shares of electric car make Tesla, Inc.(TSLA) have been on a tear for months, and ended Friday up another 17.1% so far in January, while hydrogen fuel cell company Plug Power Inc .(PLUG) shares were up 77.4% on the year to date, according to FactSet data.

Similarly, online shopping site Etsy, Inc. (ETSY) ended Friday up 14.9% on the year to date, while Stitch Fix Inc. (SFIX), a personal styling platform for clothes, ended 25.8% higher over the same stretch.

Kent Insley, chief investment officer of Tiedemann Advisors, said he's been focused on single-family home investments, either in the debt or equity space, even before Biden on Thursday promised to bolster not only renters, but mom-and-pop landlords through the remainder of the pandemic.

He pointed to the dearth of building in homes that's occurred in the dozen years since the global financial crisis.

"That's almost a decadelong period where we've underbuilt relative to demand," he told MarketWatch.

"We think single-family homes, as an asset class, benefits from highly accommodative monetary policy, low interest rates and low mortgage rates," he said.

U.S. stocks and the bond market are closed Monday for the Martin Luther King Jr. Day (https://www.marketwatch.com/story/are-financial-markets-closed-for-martin-luther-king-day-11610724028), but markets will tune into Biden's inauguration on Wednesday, as well as an update from the National Association of Home Builders. On Thursday, weekly initial jobless benefit claims will be the focus, as well as more housing data, followed Friday by manufacturing data and existing home sales for December.

See: U.S. Economic Calendar (https://www.marketwatch.com/economy-politics/calendar?mod=economy-politics)

-Joy Wiltermuth; 415-439-6400; AskNewswires@dowjones.com

	

(END) Dow Jones Newswires

January 16, 2021 09:33 ET (14:33 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.